The invention relates to the use of substituted benzamide derivatives of Formula I: Wherein: A1 and A2 are —N or —CH, so that if A1 is —N, then A2 is —CH and If A2 is —N, then A1 is —CH R is a hydrogen atom, or represents branched or unbranched —(C1-C3)-alkyl, —(C1-C3)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen or hydroxyl, —(C1-C3)—O—(C1-C3), —(C1-C3)—O—(C1-C3), wherein one, two or three hydrogen atoms may be substituted by a halogen, or R is a group wherein R3 and R4 both together or independently are halogen, hydroxyl, —(C1-C3)alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen or hydroxyl, —O—(C1-C3)-alkyl, —O—(C1-C3)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen, —O—(C1-C3)—O—(C1-C3), —O—(C1-C3)—O—(C1-C3), wherein one, two or three hydrogen atoms may be substituted by a halogen R1 and R2 both together or independently are halogen, hydroxyl, —(C1-C3)-alkyl, —(C1-C3C)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen or hydroxyl, —O—(C1-C3)-alkyl, —O—(C1-C3)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen, —O—(C1-C3)—O—(C1-C3), -0-(C1C3)—O—(C1C3), wherein one, two or three hydrogen atoms may be substituted by a halogen, their pharmaceutically acceptable salts, isomers or mixtures thereof as in vitro selective MAO-B inhibitors. The substituted benzamide derivatives of Formula I, their pharmaceutically acceptable salts, isomers or mixtures thereof are useful for the manufacture of a medicament for prevention and treatment of acute and chronic neurological disorders, cognitive and neurodegenerative diseases, more precisely for the manufacture of a medicament for prevention and treatment of neurodegenerative disorders such as Parkinsons Disease and Alzheimers Disease.
